AstraZeneca Annual Report and 18 Form 20-F Information 2005 GASTROINTESTINAL GI MEDICINES 2005 IN BRIEF PERFORMANCE 2005 compared to 2004 compared to 2005 2004 2003 2004 2003 GLOBAL SALES OF NEXIUM WERE Growth Growth $4.6 BILLION due to due to Growth exchange Growth exchange Growth Growth Growth Growth NOTICE OF ANDA FILED BY RANBAXY Sales underlying effects Sales underlying effects Sales underlying reported underlying reported $m $m $m $m $m $m $m%%%% LABORATORIES IN RELATION TO Nexium 4,633 702 48 3,883 479 102 3,302 18 19 15 18 ESOMEPRAZOLE MAGNESIUM RECEIVED Losec Prilosec 1,652 339 44 1,947 764 146 2,565 17 15 30 24 BY ASTRAZENECA IN OCTOBER 2005.
Other 70 19 1 88 7 5 76 21 20 9 16 WE COMMENCED LITIGATION AGAINST Total 6,355 344 93 5,918 278 253 5,943 5 7 4 RANBAXY IN THE US FOR INFRINGEMENT OF OUR PATENTS NOTICE OF ANDA FILED BY IVAX PIPELINE IN RELATION TO ESOMEPRAZOLE Compound Mechanism Areas under investigation Phase Estimated filing date MAGNESIUM RECEIVED BY ASTRAZENECA IN JANUARY 2006 NCEs PC 1 2 3 Europe US AZD9056 ion channel blocker inflammatory bowel disease 2008 2008 NEXIUM PARENTERAL IS APPROVED IN 68 AZD3355 inhibitor of transient lower GERD 2008 2008 COUNTRIES AND APPROVAL OF NEXIUM oesophageal sphincter FOR HEALING AND PREVENTION OF relaxations TLESR ULCERS ASSOCIATED WITH NSAID AZD9343 inhibitor of transient lower GERD 2008 2008 THERAPY HAS BEEN GRANTED IN THE oesophageal sphincter FIRST 11 EU COUNTRIES TO DATE relaxations TLESR LOSEC PRILOSEC GLOBAL SALES WERE AZD9272 GERD 2008 2008 $1.7 BILLION WITH CONTINUED STRONG AZD8081 functional GI disease 2008 2008 SALES GROWTH IN JAPAN AZD6538 GERD 2008 2008 Line extensions 1 Nexium proton pump inhibitor NSAID GI side effects Promotable Filed symptom resolution PRODUCTS Nexium proton pump inhibitor NSAID GI side effects Launched Filed Nexium esomeprazole magnesium is the ulcer healing first proton pump inhibitor PPI for the Nexium sachet proton pump inhibitor GERD Q4 2006 Filed treatment of acid-related diseases to offer formulation clinical improvements over other PPIs and Nexium proton pump inhibitor peptic ulcer bleeding 2008 2008 other treatments.
Nexium proton pump inhibitor extra-oesophageal 2008 2008 reflux disease Losec Prilosec omeprazole was the first Discontinued projects PPI, and is used for the short and long term We have discontinued these AZD7371 functional GI disease treatment of acid-related diseases.
developments as a result AZD0865 acid-related GI disease of their failure to meet their AZD5745 acid-related GI disease target product profiles.
Entocort budesonide is a locally acting corticosteroid for the treatment of IBD with better tolerability than other corticosteroids Abbreviations used in the pipeline table are explained on page 35. and greater efficacy than aminosalicylic acid medicines.
1 Authorities stated these symptoms were already captured within the GERD label.
Text stating No clinical interaction with naproxen or rofecoxib was approved.
Business Review 19 We aim to maintain our number PIPELINE In March 2004, Dr Reddys Laboratories Ltd.
In addition to exploring new areas of clinical opened a Drug Master File with the FDA relating one position in GI treatments use for Nexium and further strengthening the to the active ingredient of Nexium, esomeprazole through continued market scope of its use in current areas, we focus magnesium.
In October 2005, we received penetration for Nexium worldwide, on developing novel approaches to treating a notice from Ranbaxy Pharmaceuticals, Inc. coupled with high quality innovation GERD, inflammatory bowel disease IBD and of an Abbreviated New Drug Application ANDA functional gastrointestinal disorders FGD, filed with the FDA for esomeprazole magnesium and productivity in the research and such as irritable bowel syndrome IBS and delayed-release capsules, 20mg and 40mg, development of new GI therapies.
containing Paragraph IV certifications of invalidity and or non-infringement with respect PRODUCTS AZD3355 and AZD9343 are reflux inhibitors to Nexium.
In November 2005, AstraZeneca Nexium has been evaluated in clinical studies in phase 1 for the treatment of GERD through commenced patent infringement litigation involving 73,000 patients in over 60 countries a new targeted approach that inhibits transient in the US District Court for the District of New and offers very effective acid inhibition.
In the relaxations of the lower oesophageal sphincter.
Jersey against Ranbaxy and its affiliates treatment of reflux oesophagitis, it provides This treatment will thus aim to prevent gastroin response to its Paragraph IV certifications healing and symptom relief in more patients and oesophageal reflux from occurring whereas regarding Nexium.
Further information is set out in a shorter period of time than Losec Prilosec, PPIs are aimed at reducing the acid content on page 121. lansoprazole or pantoprazole.
It is an effective, of regurgitation.
long term therapy for patients with gastroIn January 2006, AstraZeneca received oesophageal reflux disease GERD, with Details of all compounds in the GI pipeline are a notice from IVAX Pharmaceuticals Inc. that or without oesophagitis.
For the treatment contained in the table on page 18.
IVAX Corporation has submitted an ANDA for of active peptic ulcer disease, seven day esomeprazole magnesium delayed-release Nexium triple therapy in combination with PERFORMANCE 2005 capsules, 20mg and 40mg.
AstraZeneca two antibiotics for the eradication of H. pylori Reported performance is evaluating IVAXs notice and continues to heals most patients without the need for follow Gastrointestinal sales grew by 7% to have full confidence in its intellectual property up anti-secretory therapy.
$6,355 million in 2005 from $5,918 million protecting Nexium.
For more details see in the previous year.
The slowing in the decline page 122.
Nexium is used to treat a wide range of patients of Losec sales and the continued strong with acid-related disorders, including both Losec Prilosec: Patients have benefited from performance of Nexium accounted for newly diagnosed and also patients switched over 800 million treatments with Losec Prilosec this growth.
from other therapies such as omeprazole, since launch.
Continued strong sales growth other PPIs and H2-receptor antagonists.
of Losec Omepral was seen in Japan in 2005.
Underlying performance After excluding the effects of exchange, Nexium was first launched in Sweden in August Patent protection for omeprazole, the active Gastrointestinal sales rose by 5%.
2000 and it is now available in approximately ingredient in Losec Prilosec, has expired.
100 markets, including the US, Canada and all In a small number of countries, including some In the US, Nexium sales for the full year European countries.
It has been well received major markets, patent term extensions or increased by 15% to $3,125 million.
Nexium by patients and physicians alike and close supplementary protection certificates have market share of total prescriptions in the US to 340 million patient treatments had been been granted for the active ingredient.
Further PPI market was 30.3% in December, up 3.2 administered by the end of 2005. information about the status of omeprazole percentage points versus December 2004. patents and patent litigation, including details Strong growth in dispensed tablets up 14% The parenteral form of Nexium, used when of generic omeprazole launches, is set out was partially offset by lower realised prices oral administration is not applicable for the on pages 119 and 120. resulting from performance-based contracts treatment of GERD, has now been approved and Medicaid.
Nexium was the only branded in 68 countries including the US.
During the In June, the European Commission notified PPI to gain market share in 2005.
Sales of year, further approvals have been granted in us of its decision to impose fines totalling Nexium in other markets reached $1,508 million Europe for Nexium for healing and prevention 60 million for alleged infringements of for the full year up 25% on a 2 point gain of ulcers, associated with NSAID non-steroidal European competition law relating to certain in market share.
Nexium is omeprazole intellectual property and regulatory also approved in the US for the reduction in the rights.
AstraZeneca has appealed to the Court Losec Prilosec sales were down 17% for the occurrence of gastric ulcers associated with of First Instance.
Details of this litigation are set full year to $1,652 million.
In the US sales were continuous NSAID therapy in patients at risk out on page 121.
In other markets, of developing gastric ulcers.
A regulatory filing Losec sales declined 15%, although sales for use of Nexium in paediatric GERD patients Entocort maintained its growth during 2005, increased by 25% in Japan and by 16% aged 12 years and above was submitted based on its increasing acceptance as first in China.
We also filed an line therapy for mild to moderate, active application for a formulation of delayed release Crohns disease.
granules for oral suspension of Nexium in the US in December.
AstraZeneca Annual Report and 20 Form 20-F Information 2005 GI MEDICINES CONTINUED PERFORMANCE 2004 Reported performance GI performance in 2004 was broadly the same as 2003, with sales falling by only $25 million.
Underlying performance On an underlying basis, GI sales fell by 4% $278 million as declines in Losec Prilosec exceeded growth in Nexium.
In the US, dispensed tablet volume for Nexium increased by 20% for the year.
As the impact of price was broadly neutral, reported sales growth of 10% up to $2,716 million reflected stock movements.
Nexium share of total prescriptions in the US PPI market was 27.1% in December 2004.
Sales of Nexium outside the US were up 29% on a strong performance in all major markets.
Strong volume growth was the driver behind the increase.
US sales for Prilosec for the full year were down 58% in line with the decline in prescriptions.
Outside the US, sales of Losec were also down by 16% for the year.
